Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics (NQ: FOLD )

10.91 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amicus Therapeutics

Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via Globe NewsWire
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics Announces Participation at World Muscle Society 2022
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.